BAX · Baxter International Inc.

conf –

enthusiasm:12.0 · trend:8 · quantifies:0 · impact:0 · under_radar:14 · credibility:0 · business_impact:0 · disruption:0 · confirmation:0

Enthusiasm latest 4 / prev 1 (rising)

AI was entirely absent from the Q4 FY2025 call and surfaced for the first time with meaningful specificity in Q1 FY2026, spanning three vectors: a product pipeline with integrated AI, an active AI layer on the Connected Care Foundation IoT data platform, and internal AI tooling for quality workflows. No analyst raised AI as a topic in either call, and management attached zero financial figures to any AI initiative, leaving the thesis wholly aspirational with no measurable business impact disclosed.

• We are already leveraging AI in our Connected Care Foundation, which unifies Baxter's unique data set provided by [ Internet of Things ] devices like beds, pumps and vitals to provide actionable data and analysis.
• In addition, we are using AI in frontline care to develop products that strengthen clinical insights and operational efficiency.
• We also have an active pipeline of differentiated solutions with integrated AI functionality, designed to accelerate future growth.
• We have also started to deploy AI tools to accelerate efficiency gains within internal quality workflows, such as the customer correspondence and AI-assisted corrective field action communications scheduled to be deployed later this year.

• AI-assisted corrective field action communications scheduled to be deployed later this year.
• Looking forward, we will thoughtfully embed AI directly into internal process improvements, frontline workflows and manufacturing at enterprise scale, with the goal of strengthening speed consistency, reliability while also maintaining rigorous governance and a focus on patient safety.

Est. revisions flat  ·  Fwd P/E -62.2  ·  EV/Sales 1.6x

AI claim maps to Healthcare Systems and Technologies, Medical Products And Therapies

4/10 qualitative impact   moderate  medium-term · soft evidence

Where AI matters: Connected Care IoT analytics, device software, internal quality/compliance

Q1 FY2026 cites active AI on Connected Care Foundation IoT data and starting internal quality-workflow tools, but management disclosed no revenue, margin, or productivity metrics and most growth claims sit in an undifferentiated product pipeline.

Caveats: No quantified topline or cost impact despite rising disclosure; FDA/patient-safety governance can slow AI monetization on clinical products; Pharmaceuticals (~23% of FY25 revenue) is largely outside the stated AI vectors

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 2/10

Baxter’s economics rest on regulated medical devices, disposables, and pharmaceuticals where safety, manufacturing, and hospital procurement moats are not plausibly automated away by GenAI; AI mainly augments analytics and operations rather than commoditizing the core physical consumables sold.

option liquidity: fair

proxy inputs — dollar-ADV $158M · beta 0.621 · px $19.25

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.